Avantax Advisory Services Inc. Raises Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Avantax Advisory Services Inc. increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 67.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,983 shares of the medical equipment provider’s stock after purchasing an additional 1,601 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Lantheus were worth $389,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC increased its holdings in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares in the last quarter. Hughes Financial Services LLC purchased a new position in Lantheus in the 1st quarter valued at approximately $81,000. UMB Bank n.a. raised its holdings in Lantheus by 68.2% during the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 381 shares during the last quarter. Blue Trust Inc. boosted its position in Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 633 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Lantheus by 29.3% during the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 298 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $51.87 on Thursday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The company’s 50 day simple moving average is $77.09 and its 200 day simple moving average is $87.42. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of 14.74 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analysts’ expectations of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.69 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LNTH. Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, B. Riley cut their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.